retatrutide ly3437943 glp-1 gip glucagon receptor agonist LY3437943, a novel triple glucagon, GIP, and for glycemic control and weight loss: From discovery to clinical proof of concept What Is Retatrutide? The Triple

Gydesen S, Hjuler ST, Freving Z, Andreassen KV, Sonne N, Hellgren LI, Karsdal MA, Henriksen K

List of GLP-1 ini6al approvals since 2005 *products no longer on the market Notable GLP-1 Agonists for Obesity The first GLP-1 drug approved for obesity was Saxenda (liraglutide) from Novo Nordisk, a twice-daily injectable that demonstrated a 7% weight reduction over a year upon its approval

Obesity, primarily associated with the increased burden of non-communicable diseases (NCDs), has been linked to healthcare costs approximately 30% higher than those of individuals with normal body weight [9]

How does GLP-1 Up compare

however, the type, severity, and frequency of these effects may differ between agents, formulations, and dosing schedules